Skip to main content
. 2017 May 27;102(6):961–969. doi: 10.1002/cpt.711

Table 3.

Range of estimated (simulated) hepatocyte loss as a function of observed plasma peak alanine transaminase (ALT) range in phase I cimaglermin alfa‐treated subjects with 100% apoptosis or 100% necrosis as the cell death modality

Peak ALT range (U/L) Hepatocyte loss (%)
estimated with 100% apoptosis
(lower bound – upper bound)
Hepatocyte loss (%)
estimated with 100% necrosis
(lower bound – upper bound)
1–100 0.0–7.0 0.0–2.8
101–200 4.9–9.9 2.7–6.2
201–300 6.6–12.4 2.7–7.8